MISSISSAUGA, Ontario, Dec. 23, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today announced the successful syndication of $500 million of incremental term loans under its existing senior secured credit facilities in connection with its acquisition of iNova. The incremental term loans will mature in April 2016 and have terms that are customary for this type of financing. The facility closed on December 19, 2011.
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.
Laurie W. Little